ChemFeeds Site Navigation:
Journal Selection:
Search:

1) PPAR-{beta}/{delta} Inhibits Human Breast Cancer Tumorigenicity (Molecular Cancer Therapeutics) Sunday April 6th 2014


2) Targeting Malignant Brain Tumors (Molecular Cancer Therapeutics) Sunday April 6th 2014


3) Single-Cell Pharmacokinetics of PARP Inhibitors (Molecular Cancer Therapeutics) Sunday April 6th 2014


4) Decreased miR-340 in Bone Marrow of Metastatic CRC (Molecular Cancer Therapeutics) Sunday April 6th 2014


5) MSC Promote Tumor Cell Survival (Molecular Cancer Therapeutics) Sunday April 6th 2014


6) Antiglioma Activity of Interferon-{beta} (Molecular Cancer Therapeutics) Sunday April 6th 2014


7) PP2A Inhibition in Colorectal Cancer (Molecular Cancer Therapeutics) Sunday April 6th 2014


8) Archazolid Induces Anoikis in Metastatic Cancer Cells (Molecular Cancer Therapeutics) Sunday April 6th 2014


9) A Neutralizing Anti-LGALS3BP Antibody (Molecular Cancer Therapeutics) Sunday April 6th 2014


10) EMP2 Is a Novel Therapeutic Target in Breast Cancer (Molecular Cancer Therapeutics) Sunday April 6th 2014


11) Antitumor Activity of the Glutaminase Inhibitor CB-839 in TNBC (Molecular Cancer Therapeutics) Sunday April 6th 2014


12) AMG 925, a FLT3/CDK4 Dual Inhibitor for Treating AML (Molecular Cancer Therapeutics) Sunday April 6th 2014


13) Preclinical Activity of Birinapant, a Bivalent SMAC Mimetic (Molecular Cancer Therapeutics) Sunday April 6th 2014


14) Inhibition of SREBPs in Prostate Cancer (Molecular Cancer Therapeutics) Sunday April 6th 2014


15) Lymphoma Tumor Regression with EZH2 Inhibitor (Molecular Cancer Therapeutics) Sunday April 6th 2014


16) Imipramine-Blue Treatment of Burkitt Lymphoma (Molecular Cancer Therapeutics) Sunday April 6th 2014


17) E6201 Treatment for Acquired Resistance to Vemurafenib (Molecular Cancer Therapeutics) Sunday April 6th 2014


18) Monensin Inhibits Wnt/{beta}-Catenin Signaling (Molecular Cancer Therapeutics) Sunday April 6th 2014


19) Niclosamide Is Cytotoxic to CSCs (Molecular Cancer Therapeutics) Sunday April 6th 2014


20) Gramicidin A Inhibits Hypoxia-Inducible Factor (Molecular Cancer Therapeutics) Sunday April 6th 2014


21) Dovitinib and ICI182.780 in Endometrial Carcinoma (Molecular Cancer Therapeutics) Sunday April 6th 2014


22) PDT with a Glucose-Conjugated Chlorin for GIST (Molecular Cancer Therapeutics) Sunday April 6th 2014


23) Sorafenib Inhibits ABCG2 and Overcomes Irinotecan Resistance--Response (Molecular Cancer Therapeutics) Monday March 10th 2014


24) Sorafenib Inhibits ABCG2 and Overcomes Irinotecan Resistance--Letter (Molecular Cancer Therapeutics) Monday March 10th 2014


25) Identification of Cancer-Associated CD43 Mimotopes (Molecular Cancer Therapeutics) Monday March 10th 2014


26) Regulation of DPD by miR-27a and miR-27b (Molecular Cancer Therapeutics) Monday March 10th 2014


27) Exploiting Lipid Dependence in Ras-Driven Cancer (Molecular Cancer Therapeutics) Monday March 10th 2014


28) STAG2 Mutation and PARP Inhibition in Glioblastoma Cells (Molecular Cancer Therapeutics) Monday March 10th 2014


29) Masitinib Restores ABCC10-Mediated Paclitaxel Sensitivity (Molecular Cancer Therapeutics) Monday March 10th 2014


30) Synuclein {gamma} and Antimicrotubule Drug Resistance (Molecular Cancer Therapeutics) Monday March 10th 2014


31) Acetylation of FOXO-1 by Capsaicin Causes Apoptosis (Molecular Cancer Therapeutics) Monday March 10th 2014


32) XPO1 Inhibition Represses STAT3 (Molecular Cancer Therapeutics) Monday March 10th 2014


33) SCH727965 Inhibits UPR (Molecular Cancer Therapeutics) Monday March 10th 2014


34) Design of Solid Tumor-Penetrating Antibody (Molecular Cancer Therapeutics) Monday March 10th 2014


35) Fc-TRAIL Conjugation Improves Activity In Vitro and In Vivo (Molecular Cancer Therapeutics) Monday March 10th 2014


36) TPZ Sensitizes HCC to Topo I Inhibitors (Molecular Cancer Therapeutics) Monday March 10th 2014


37) TPCA-1 Inhibits STAT3 and NF-{kappa}B Activation in Lung Cancer (Molecular Cancer Therapeutics) Monday March 10th 2014


38) Niclosamide Reverses Radioresistance (Molecular Cancer Therapeutics) Monday March 10th 2014


39) Antiglioma Actions of Compound C (Molecular Cancer Therapeutics) Monday March 10th 2014


40) Orlistat Is Antimetastatic in Oral Cancer (Molecular Cancer Therapeutics) Monday March 10th 2014


41) MET and Top1 Inhibitors Combine to Decrease SCLC Viability (Molecular Cancer Therapeutics) Monday March 10th 2014


42) Mcl-1 Inhibitors as Potential Therapeutics for Pancreatic Cancer (Molecular Cancer Therapeutics) Monday March 10th 2014


43) Advances in NSCLC Diagnosis and Treatment (Molecular Cancer Therapeutics) Monday March 10th 2014


44) Correction: Aerosol Delivery of Urocanic Acid-Modified Chitosan/Programmed Cell Death 4 Complex Regulated Apoptosis, Cell Cycle, and Angiogenesis in Lungs of K-ras Null Mice (Molecular Cancer Therapeutics) Sunday February 9th 2014


45) Evaluation of Potential Onartuzumab Proximal Biomarkers (Molecular Cancer Therapeutics) Sunday February 9th 2014


46) Plastin as a Predictive Marker in Stage II/III Colon Cancer (Molecular Cancer Therapeutics) Sunday February 9th 2014


47) AR Sensitizes Breast Carcinomas to NVP-BEZ235 (Molecular Cancer Therapeutics) Sunday February 9th 2014


48) mTOR Targeting in Myeloma (Molecular Cancer Therapeutics) Sunday February 9th 2014


49) Oatp1a/1b Proteins Alter Irinotecan Pharmacokinetics and Ces1 Levels (Molecular Cancer Therapeutics) Sunday February 9th 2014


50) SDF-1{alpha}/PDGF-B and BM-Derived Pericytes in Ewing Tumors (Molecular Cancer Therapeutics) Sunday February 9th 2014


51) Acquired Resistance to Dasatinib in Lung Cancer (Molecular Cancer Therapeutics) Sunday February 9th 2014


52) Jak Inhibition Limits Gastrointestinal Tumor Growth (Molecular Cancer Therapeutics) Sunday February 9th 2014


53) GSK3 Inhibitors, Potential Neuroblastoma Therapeutic Agents (Molecular Cancer Therapeutics) Sunday February 9th 2014


54) EMT and Resistance to Gefitinib by miR-134/487b/655 Cluster (Molecular Cancer Therapeutics) Sunday February 9th 2014


55) PARP Trapping by BMN 673 (Molecular Cancer Therapeutics) Sunday February 9th 2014


56) Effect of Photoimmunotherapy in a Mixed Tumor Model (Molecular Cancer Therapeutics) Sunday February 9th 2014


57) MM-141 Blocks Redundant Cancer Survival Pathways (Molecular Cancer Therapeutics) Sunday February 9th 2014


58) Preclinical Properties of an IGF Ligand-Neutralizing mAb (Molecular Cancer Therapeutics) Sunday February 9th 2014


59) Fully Human Anti-Hedgehog Antibodies (Molecular Cancer Therapeutics) Sunday February 9th 2014


60) Click-PEGylated Fusion Toxin (Molecular Cancer Therapeutics) Sunday February 9th 2014


61) LY2228820, a p38 MAPK Inhibitor with Antitumor Activity (Molecular Cancer Therapeutics) Sunday February 9th 2014


62) Ganetespib Activity in Vemurafenib-Resistant Melanoma (Molecular Cancer Therapeutics) Sunday February 9th 2014


63) Mahanine Disrupts AR Signaling in Prostate Cancer Cells (Molecular Cancer Therapeutics) Sunday February 9th 2014


64) ASP3026 Induces Tumor Regression and Prolongs Survival (Molecular Cancer Therapeutics) Sunday February 9th 2014


65) IGFBP-3 and EGFR Inhibition in Triple-Negative Breast Cancer (Molecular Cancer Therapeutics) Sunday February 9th 2014


66) MPS1 Kinase as a Target in Pancreatic Ductal Adenocarcinoma (Molecular Cancer Therapeutics) Sunday February 9th 2014


67) Clodronate Prodrug Is Cytotoxic against Melanoma (Molecular Cancer Therapeutics) Sunday February 9th 2014


68) GSK-3 Inhibition in Renal Cancer (Molecular Cancer Therapeutics) Sunday February 9th 2014


69) Microtubule-Targeting Agents for Cancer Chemotherapy (Molecular Cancer Therapeutics) Sunday February 9th 2014


70) Correction: MicroRNA Regulation of Oncolytic Adenovirus 6 for Selective Treatment of Castration-Resistant Prostate Cancer (Molecular Cancer Therapeutics) Tuesday January 14th 2014


71) Correction: Chemotherapy Counteracts Metastatic Dissemination Induced by Antiangiogenic Treatment in Mice (Molecular Cancer Therapeutics) Tuesday January 14th 2014


72) Proteomics of Drug-Resistant Cancer Cell Lines (Molecular Cancer Therapeutics) Tuesday January 14th 2014


73) MRP1 Overexpression Confers Poor Prognosis in High-Risk STS (Molecular Cancer Therapeutics) Tuesday January 14th 2014


74) Camptothecin Interferes with HIF-1{alpha} via microRNAs (Molecular Cancer Therapeutics) Tuesday January 14th 2014


75) PTPH1 Increases Antihormone Sensitivity by Targeting ER/Y537 (Molecular Cancer Therapeutics) Tuesday January 14th 2014


76) Sorafenib Suppresses JNK-Dependent Apoptosis (Molecular Cancer Therapeutics) Tuesday January 14th 2014


77) Genetic Screen of DNA Repair for Topoisomerase Inhibitors (Molecular Cancer Therapeutics) Tuesday January 14th 2014


78) Differential Anti-VEGF-A Therapeutic Effects (Molecular Cancer Therapeutics) Tuesday January 14th 2014


79) FAK and Docetaxel Resistance (Molecular Cancer Therapeutics) Tuesday January 14th 2014


80) Reversible Action of DAT1 in Cancer Cells (Molecular Cancer Therapeutics) Tuesday January 14th 2014


81) Therapeutic Vector for Angiogenesis Normalization Therapy (Molecular Cancer Therapeutics) Tuesday January 14th 2014


82) Targeting SphK Induces Apoptosis and PEL Regression In Vivo (Molecular Cancer Therapeutics) Tuesday January 14th 2014


83) FdUrd-Induced Radiosensitization of Myeloma Stem-like Cells (Molecular Cancer Therapeutics) Tuesday January 14th 2014


84) Tivantinib, Crizotinib, and Thyroid Cancer Cells (Molecular Cancer Therapeutics) Tuesday January 14th 2014


85) RalA Phosphorylation and MLN8237 (Molecular Cancer Therapeutics) Tuesday January 14th 2014


86) Combining IL-15 and 4-1BBL in an Antibody Fusion Protein (Molecular Cancer Therapeutics) Tuesday January 14th 2014


87) Tetravalent Fusion Proteins (Molecular Cancer Therapeutics) Tuesday January 14th 2014


88) Bispecific Antibody Cotargeting HER2 and IGF-IR (Molecular Cancer Therapeutics) Tuesday January 14th 2014


89) Regulation of Immunotoxin Action by HCK (Molecular Cancer Therapeutics) Tuesday January 14th 2014


90) Modified NPs for Enhanced siRNA Bladder Delivery (Molecular Cancer Therapeutics) Tuesday January 14th 2014


91) PI3K p110{alpha} Signaling Promotes Lapatinib Resistance (Molecular Cancer Therapeutics) Tuesday January 14th 2014


92) Lappaol F as a Novel Antitumor Agent (Molecular Cancer Therapeutics) Tuesday January 14th 2014


93) Synergism of BMS-777607 and AZD8055 on Polyploid PDAC Cells (Molecular Cancer Therapeutics) Tuesday January 14th 2014


94) SC-60 for the Treatment of HCC (Molecular Cancer Therapeutics) Tuesday January 14th 2014


95) Combination of Vemurafenib and ABI Overcomes Drug Resistance (Molecular Cancer Therapeutics) Tuesday January 14th 2014


96) IAP Inhibitors Promote TRAIL-Induced Cell Death via Caspase-8 (Molecular Cancer Therapeutics) Tuesday January 14th 2014


97) A Message from the New Editor-in-Chief (Molecular Cancer Therapeutics) Tuesday January 14th 2014


98) Acknowledgment to Reviewers (Molecular Cancer Therapeutics) Thursday December 5th 2013


View: prev | next

#RealTimeChem:

Announcements:


Mitch Andre Garcia's Chem Feeds 2008-present

Some images have been reproduced by permission of The Royal Society of Chemistry. (RSC' RSS Policy)
Other images have been reproduced with permission of the American Chemical Society. (ACS' RSS Policy)
Few images have been reproduced with pending permission of Wiley-VCH. ()